 | • レポートコード：D005-00129 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、膀胱がん治療・診断の世界市場を広く調査・分析し、今後の市場展望をまとめております。膀胱がん治療・診断の種類別市場規模（化学療法、免疫療法、放射線療法、その他）、用途別市場規模（病院、腫瘍治療センター、外来手術センター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、Sanofi、Novartis、GlaxoSmithKline、Roche、Merck、Celgene Corporation、Eli Lilly、Bristol-Myers Squibb、AstraZeneca ・地域別グローバル市場分析 2015年-2020年 ・膀胱がん治療・診断の北米市場（アメリカ、カナダ、メキシコ） ・膀胱がん治療・診断のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・膀胱がん治療・診断のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・膀胱がん治療・診断の南米市場（ブラジル、アルゼンチン） ・膀胱がん治療・診断の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：化学療法、免疫療法、放射線療法、その他 ・用途別分析：病院、腫瘍治療センター、外来手術センター、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Bladder Cancer Therapeutics and Diagnostics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 6.6% in the forecast period of 2020 to 2025 and will expected to reach USD 551.5 million by 2025, from USD 427.6 million in 2019.
The Bladder Cancer Therapeutics and Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Bladder Cancer Therapeutics and Diagnostics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Bladder Cancer Therapeutics and Diagnostics market has been segmented into:
Chemotherapy
Immunotherapy
Radiation Therapy
Others
By Application, Bladder Cancer Therapeutics and Diagnostics has been segmented into:
Hospitals
Oncology Treatment Centers
Ambulatory Surgery Centers
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Bladder Cancer Therapeutics and Diagnostics market presented in the report. This section sheds light on the sales growth of different regional and country-level Bladder Cancer Therapeutics and Diagnostics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Bladder Cancer Therapeutics and Diagnostics market.
The report offers in-depth assessment of the growth and other aspects of the Bladder Cancer Therapeutics and Diagnostics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Bladder Cancer Therapeutics and Diagnostics Market Share Analysis
Bladder Cancer Therapeutics and Diagnostics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Bladder Cancer Therapeutics and Diagnostics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Bladder Cancer Therapeutics and Diagnostics sales, revenue and market share for each player covered in this report.
The major players covered in Bladder Cancer Therapeutics and Diagnostics are:
Pfizer
Sanofi
Novartis
GlaxoSmithKline
Roche
Merck
Celgene Corporation
Eli Lilly
Bristol-Myers Squibb
AstraZeneca
Table of Contents
1 Bladder Cancer Therapeutics and Diagnostics Market Overview
1.1 Product Overview and Scope of Bladder Cancer Therapeutics and Diagnostics
1.2 Classification of Bladder Cancer Therapeutics and Diagnostics by Type
1.2.1 Global Bladder Cancer Therapeutics and Diagnostics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Type in 2019
1.2.3 Chemotherapy
1.2.4 Immunotherapy
1.2.5 Radiation Therapy
1.2.6 Others
1.3 Global Bladder Cancer Therapeutics and Diagnostics Market by Application
1.3.1 Overview: Global Bladder Cancer Therapeutics and Diagnostics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Oncology Treatment Centers
1.3.4 Ambulatory Surgery Centers
1.3.5 Others
1.4 Global Bladder Cancer Therapeutics and Diagnostics Market by Regions
1.4.1 Global Bladder Cancer Therapeutics and Diagnostics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Bladder Cancer Therapeutics and Diagnostics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Bladder Cancer Therapeutics and Diagnostics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Bladder Cancer Therapeutics and Diagnostics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Bladder Cancer Therapeutics and Diagnostics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Bladder Cancer Therapeutics and Diagnostics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Bladder Cancer Therapeutics and Diagnostics Status and Prospect (2015-2025)
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Bladder Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Sanofi SWOT Analysis
2.2.4 Sanofi Product and Services
2.2.5 Sanofi Bladder Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Novartis SWOT Analysis
2.3.4 Novartis Product and Services
2.3.5 Novartis Bladder Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 GlaxoSmithKline SWOT Analysis
2.4.4 GlaxoSmithKline Product and Services
2.4.5 GlaxoSmithKline Bladder Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Roche
2.5.1 Roche Details
2.5.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Roche SWOT Analysis
2.5.4 Roche Product and Services
2.5.5 Roche Bladder Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Merck SWOT Analysis
2.6.4 Merck Product and Services
2.6.5 Merck Bladder Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.7 Celgene Corporation
2.7.1 Celgene Corporation Details
2.7.2 Celgene Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Celgene Corporation SWOT Analysis
2.7.4 Celgene Corporation Product and Services
2.7.5 Celgene Corporation Bladder Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.8 Eli Lilly
2.8.1 Eli Lilly Details
2.8.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Eli Lilly SWOT Analysis
2.8.4 Eli Lilly Product and Services
2.8.5 Eli Lilly Bladder Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.9 Bristol-Myers Squibb
2.9.1 Bristol-Myers Squibb Details
2.9.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Bristol-Myers Squibb SWOT Analysis
2.9.4 Bristol-Myers Squibb Product and Services
2.9.5 Bristol-Myers Squibb Bladder Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
2.10 AstraZeneca
2.10.1 AstraZeneca Details
2.10.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 AstraZeneca SWOT Analysis
2.10.4 AstraZeneca Product and Services
2.10.5 AstraZeneca Bladder Cancer Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Bladder Cancer Therapeutics and Diagnostics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Bladder Cancer Therapeutics and Diagnostics Players Market Share
3.2.2 Top 10 Bladder Cancer Therapeutics and Diagnostics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Bladder Cancer Therapeutics and Diagnostics Revenue and Market Share by Regions
4.2 North America Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
4.3 Europe Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
4.5 South America Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
5 North America Bladder Cancer Therapeutics and Diagnostics Revenue by Countries
5.1 North America Bladder Cancer Therapeutics and Diagnostics Revenue by Countries (2015-2020)
5.2 USA Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
5.3 Canada Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
5.4 Mexico Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
6 Europe Bladder Cancer Therapeutics and Diagnostics Revenue by Countries
6.1 Europe Bladder Cancer Therapeutics and Diagnostics Revenue by Countries (2015-2020)
6.2 Germany Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
6.3 UK Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
6.4 France Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
6.5 Russia Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
6.6 Italy Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Revenue by Countries
7.1 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Revenue by Countries (2015-2020)
7.2 China Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
7.3 Japan Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
7.4 Korea Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
7.5 India Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
8 South America Bladder Cancer Therapeutics and Diagnostics Revenue by Countries
8.1 South America Bladder Cancer Therapeutics and Diagnostics Revenue by Countries (2015-2020)
8.2 Brazil Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
8.3 Argentina Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Bladder Cancer Therapeutics and Diagnostics by Countries
9.1 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
9.3 UAE Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
9.4 Egypt Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
9.5 South Africa Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Bladder Cancer Therapeutics and Diagnostics Revenue and Market Share by Type (2015-2020)
10.2 Global Bladder Cancer Therapeutics and Diagnostics Market Forecast by Type (2019-2024)
10.3 Chemotherapy Revenue Growth Rate (2015-2025)
10.4 Immunotherapy Revenue Growth Rate (2015-2025)
10.5 Radiation Therapy Revenue Growth Rate (2015-2025)
10.6 Others Revenue Growth Rate (2015-2025)
11 Global Bladder Cancer Therapeutics and Diagnostics Market Segment by Application
11.1 Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Application (2015-2020)
11.2 Bladder Cancer Therapeutics and Diagnostics Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Oncology Treatment Centers Revenue Growth (2015-2020)
11.5 Ambulatory Surgery Centers Revenue Growth (2015-2020)
11.6 Others Revenue Growth (2015-2020)
12 Global Bladder Cancer Therapeutics and Diagnostics Market Size Forecast (2021-2025)
12.1 Global Bladder Cancer Therapeutics and Diagnostics Market Size Forecast (2021-2025)
12.2 Global Bladder Cancer Therapeutics and Diagnostics Market Forecast by Regions (2021-2025)
12.3 North America Bladder Cancer Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
12.4 Europe Bladder Cancer Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
12.6 South America Bladder Cancer Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Bladder Cancer Therapeutics and Diagnostics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Bladder Cancer Therapeutics and Diagnostics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Bladder Cancer Therapeutics and Diagnostics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Pfizer Corporate Information, Location and Competitors
Table 6. Pfizer Bladder Cancer Therapeutics and Diagnostics Major Business
Table 7. Pfizer Bladder Cancer Therapeutics and Diagnostics Total Revenue (USD Million) (2017-2018)
Table 8. Pfizer SWOT Analysis
Table 9. Pfizer Bladder Cancer Therapeutics and Diagnostics Product and Solutions
Table 10. Pfizer Bladder Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Sanofi Corporate Information, Location and Competitors
Table 12. Sanofi Bladder Cancer Therapeutics and Diagnostics Major Business
Table 13. Sanofi Bladder Cancer Therapeutics and Diagnostics Total Revenue (USD Million) (2018-2019)
Table 14. Sanofi SWOT Analysis
Table 15. Sanofi Bladder Cancer Therapeutics and Diagnostics Product and Solutions
Table 16. Sanofi Bladder Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Novartis Corporate Information, Location and Competitors
Table 18. Novartis Bladder Cancer Therapeutics and Diagnostics Major Business
Table 19. Novartis Bladder Cancer Therapeutics and Diagnostics Total Revenue (USD Million) (2017-2018)
Table 20. Novartis SWOT Analysis
Table 21. Novartis Bladder Cancer Therapeutics and Diagnostics Product and Solutions
Table 22. Novartis Bladder Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. GlaxoSmithKline Corporate Information, Location and Competitors
Table 24. GlaxoSmithKline Bladder Cancer Therapeutics and Diagnostics Major Business
Table 25. GlaxoSmithKline Bladder Cancer Therapeutics and Diagnostics Total Revenue (USD Million) (2017-2018)
Table 26. GlaxoSmithKline SWOT Analysis
Table 27. GlaxoSmithKline Bladder Cancer Therapeutics and Diagnostics Product and Solutions
Table 28. GlaxoSmithKline Bladder Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Roche Corporate Information, Location and Competitors
Table 30. Roche Bladder Cancer Therapeutics and Diagnostics Major Business
Table 31. Roche Bladder Cancer Therapeutics and Diagnostics Total Revenue (USD Million) (2017-2018)
Table 32. Roche SWOT Analysis
Table 33. Roche Bladder Cancer Therapeutics and Diagnostics Product and Solutions
Table 34. Roche Bladder Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Merck Corporate Information, Location and Competitors
Table 36. Merck Bladder Cancer Therapeutics and Diagnostics Major Business
Table 37. Merck Bladder Cancer Therapeutics and Diagnostics Total Revenue (USD Million) (2017-2018)
Table 38. Merck SWOT Analysis
Table 39. Merck Bladder Cancer Therapeutics and Diagnostics Product and Solutions
Table 40. Merck Bladder Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Celgene Corporation Corporate Information, Location and Competitors
Table 42. Celgene Corporation Bladder Cancer Therapeutics and Diagnostics Major Business
Table 43. Celgene Corporation Bladder Cancer Therapeutics and Diagnostics Total Revenue (USD Million) (2017-2018)
Table 44. Celgene Corporation SWOT Analysis
Table 45. Celgene Corporation Bladder Cancer Therapeutics and Diagnostics Product and Solutions
Table 46. Celgene Corporation Bladder Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Eli Lilly Corporate Information, Location and Competitors
Table 48. Eli Lilly Bladder Cancer Therapeutics and Diagnostics Major Business
Table 49. Eli Lilly Bladder Cancer Therapeutics and Diagnostics Total Revenue (USD Million) (2017-2018)
Table 50. Eli Lilly SWOT Analysis
Table 51. Eli Lilly Bladder Cancer Therapeutics and Diagnostics Product and Solutions
Table 52. Eli Lilly Bladder Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 54. Bristol-Myers Squibb Bladder Cancer Therapeutics and Diagnostics Major Business
Table 55. Bristol-Myers Squibb Bladder Cancer Therapeutics and Diagnostics Total Revenue (USD Million) (2017-2018)
Table 56. Bristol-Myers Squibb SWOT Analysis
Table 57. Bristol-Myers Squibb Bladder Cancer Therapeutics and Diagnostics Product and Solutions
Table 58. Bristol-Myers Squibb Bladder Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. AstraZeneca Corporate Information, Location and Competitors
Table 60. AstraZeneca Bladder Cancer Therapeutics and Diagnostics Major Business
Table 61. AstraZeneca Bladder Cancer Therapeutics and Diagnostics Total Revenue (USD Million) (2017-2018)
Table 62. AstraZeneca SWOT Analysis
Table 63. AstraZeneca Bladder Cancer Therapeutics and Diagnostics Product and Solutions
Table 64. AstraZeneca Bladder Cancer Therapeutics and Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Global Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) by Players (2015-2020)
Table 66. Global Bladder Cancer Therapeutics and Diagnostics Revenue Share by Players (2015-2020)
Table 67. Global Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) by Regions (2015-2020)
Table 68. Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Regions (2015-2020)
Table 69. North America Bladder Cancer Therapeutics and Diagnostics Revenue by Countries (2015-2020)
Table 70. North America Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Countries (2015-2020)
Table 71. Europe Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) by Countries (2015-2020)
Table 72. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) by Countries (2015-2020)
Table 73. South America Bladder Cancer Therapeutics and Diagnostics Revenue by Countries (2015-2020)
Table 74. South America Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Countries (2015-2020)
Table 75. Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) by Countries (2015-2020)
Table 76. Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Countries (2015-2020)
Table 77. Global Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) by Type (2015-2020)
Table 78. Global Bladder Cancer Therapeutics and Diagnostics Revenue Share by Type (2015-2020)
Table 79. Global Bladder Cancer Therapeutics and Diagnostics Revenue Forecast by Type (2021-2025)
Table 80. Global Bladder Cancer Therapeutics and Diagnostics Revenue by Application (2015-2020)
Table 81. Global Bladder Cancer Therapeutics and Diagnostics Revenue Share by Application (2015-2020)
Table 82. Global Bladder Cancer Therapeutics and Diagnostics Revenue Forecast by Application (2021-2025)
Table 83. Global Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Bladder Cancer Therapeutics and Diagnostics Picture
Figure 2. Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Type in 2019
Figure 3. Chemotherapy Picture
Figure 4. Immunotherapy Picture
Figure 5. Radiation Therapy Picture
Figure 6. Others Picture
Figure 7. Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Application in 2019
Figure 8. Hospitals Picture
Figure 9. Oncology Treatment Centers Picture
Figure 10. Ambulatory Surgery Centers Picture
Figure 11. Others Picture
Figure 12. Global Bladder Cancer Therapeutics and Diagnostics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Bladder Cancer Therapeutics and Diagnostics Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Bladder Cancer Therapeutics and Diagnostics Revenue Market Share in 2019
Figure 21. Global Top 10 Players Bladder Cancer Therapeutics and Diagnostics Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Regions (2015-2020)
Figure 25. Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Regions in 2018
Figure 26. North America Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 27. Europe Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 29. South America Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 31. North America Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Countries (2015-2020)
Figure 32. North America Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Countries in 2019
Figure 33. USA Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 34. Canada Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 36. Europe Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Countries in 2019
Figure 38. Germany Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 39. UK Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 40. France Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 41. Russia Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 42. Italy Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Countries in 2019
Figure 45. China Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 46. Japan Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 47. Korea Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 48. India Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 50. South America Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Countries (2015-2020)
Figure 51. South America Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Countries in 2019
Figure 52. Brazil Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 57. UAE Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Bladder Cancer Therapeutics and Diagnostics Revenue and Growth Rate (2015-2020)
Figure 60. Global Bladder Cancer Therapeutics and Diagnostics Revenue Share by Type (2015-2020)
Figure 61. Global Bladder Cancer Therapeutics and Diagnostics Revenue Share by Type in 2019
Figure 62. Global Bladder Cancer Therapeutics and Diagnostics Market Share Forecast by Type (2021-2025)
Figure 63. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 64. Global Immunotherapy Revenue Growth Rate (2015-2020)
Figure 65. Global Radiation Therapy Revenue Growth Rate (2015-2020)
Figure 66. Global Others Revenue Growth Rate (2015-2020)
Figure 67. Global Bladder Cancer Therapeutics and Diagnostics Revenue Share by Application (2015-2020)
Figure 68. Global Bladder Cancer Therapeutics and Diagnostics Revenue Share by Application in 2019
Figure 69. Global Bladder Cancer Therapeutics and Diagnostics Market Share Forecast by Application (2021-2025)
Figure 70. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 71. Global Oncology Treatment Centers Revenue Growth Rate (2015-2020)
Figure 72. Global Ambulatory Surgery Centers Revenue Growth Rate (2015-2020)
Figure 73. Global Others Revenue Growth Rate (2015-2020)
Figure 74. Global Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Bladder Cancer Therapeutics and Diagnostics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Bladder Cancer Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
Figure 78. Europe Bladder Cancer Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
Figure 80. South America Bladder Cancer Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
大腸がん診断＆治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Colorectal Cancer Diagnosis and Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The …- 移行上皮がん治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Transitional Cell Cancer Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Transit…
- 非侵襲的がん診断の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Noninvasive Cancer Diagnostics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.7% in the forecast period of 2020 to 2025 and will expected to reach USD 127940 million by 2025, from USD 110450 million in 2019. The Nonin…
- 頭頸部がん治療薬/治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Head and Neck Cancer Drugs/Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.0% in the forecast period of 2020 to 2025 and will expected to reach USD 1466.9 million by 2025, from USD 1255.8 million in 2019. …
- ペット用がん治療の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Pet Cancer Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.9% in the forecast period of 2020 to 2025 and will expected to reach USD 206.2 million by 2025, from USD 164.2 million in 2019. The Pet Cancer The…